Gene* | All patients | MSS group | ||
Responders, n/N | ORR, % (95% CI) | Responders, n/N | ORR, % (95% CI) | |
PIK3CA | ||||
Mutation | 10/27 | 37.0 (19.4 to 57.6) | 7/21 | 33.3 (14.6 to 57.0) |
No mutation | 14/26 | 53.8 (33.4 to 73.4) | 11/22 | 50.0 (28.2 to 71.8) |
PTEN | ||||
Mutation | 7/17 | 41.2 (18.4 to 67.1) | 3/9 | 33.3 (7.5 to 70.1) |
No mutation | 17/36 | 47.2 (30.4 to 64.5) | 15/34 | 44.1 (27.2 to 62.1) |
TP53 | ||||
Mutation | 11/25 | 44.0 (24.4 to 65.1) | 10/23 | 43.5 (23.2 to 65.5) |
No mutation | 13/28 | 46.4 (27.5 to 66.1) | 8/20 | 40.0 (19.1 to 63.9) |
*Hotspot mutations in PIK3CA (oncogene); deleterious mutations in PTEN or TP53 (tumor suppressor genes).
MSS, microsatellite stable; ORR, objective response rate.